vs
Bone Biologics Corp（BBLG）与Cadre Holdings, Inc.（CDRE）财务数据对比。点击上方公司名可切换其他公司
Cadre Holdings, Inc.的季度营收约是Bone Biologics Corp的655780.4倍（$167.2M vs $255）。Cadre Holdings, Inc.净利率更高（7.0% vs -339596.1%，领先339603.1%）。Cadre Holdings, Inc.同比增速更快（-5.0% vs -54.1%）
Bone Biologics Corp是一家临床阶段生物技术企业，专注研发用于脊柱融合等骨科手术的骨再生修复生物制剂，主要面向美国医疗市场，核心业务覆盖骨科护理及再生医学领域。
Cadre Holdings, Inc.是美国金融科技企业，面向个人及机构客户提供房地产投资项目直投渠道，覆盖纽约等地的商业地产。公司打造的投资平台支持投资者自主选择参与的具体交易项目，且投资门槛远低于全额收购物业所需资金，让不动产投资变得更接近股票交易，获得财经媒体的广泛认可。
BBLG vs CDRE — 直观对比
营收规模更大
CDRE
是对方的655780.4倍
$255
营收增速更快
CDRE
高出49.2%
-54.1%
净利率更高
CDRE
高出339603.1%
-339596.1%
损益表 — Q1 2024 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $255 | $167.2M |
| 净利润 | $-866.0K | $11.7M |
| 毛利率 | — | 43.4% |
| 营业利润率 | -354327.8% | 12.2% |
| 净利率 | -339596.1% | 7.0% |
| 营收同比 | -54.1% | -5.0% |
| 净利润同比 | 76.7% | -9.6% |
| 每股收益（稀释后） | $-1.31 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BBLGCDRE
| Q4 25 | — | $167.2M | ||
| Q3 25 | — | $155.9M | ||
| Q2 25 | — | $157.1M | ||
| Q1 25 | — | $130.1M | ||
| Q4 24 | — | $176.0M | ||
| Q3 24 | — | $109.4M | ||
| Q2 24 | — | $144.3M | ||
| Q1 24 | $255 | $137.9M |
净利润BBLGCDRE
| Q4 25 | — | $11.7M | ||
| Q3 25 | — | $10.9M | ||
| Q2 25 | — | $12.2M | ||
| Q1 25 | — | $9.2M | ||
| Q4 24 | — | $13.0M | ||
| Q3 24 | — | $3.7M | ||
| Q2 24 | — | $12.6M | ||
| Q1 24 | $-866.0K | $6.9M |
毛利率BBLGCDRE
| Q4 25 | — | 43.4% | ||
| Q3 25 | — | 42.7% | ||
| Q2 25 | — | 40.9% | ||
| Q1 25 | — | 43.1% | ||
| Q4 24 | — | 43.9% | ||
| Q3 24 | — | 36.6% | ||
| Q2 24 | — | 40.6% | ||
| Q1 24 | — | 41.8% |
营业利润率BBLGCDRE
| Q4 25 | — | 12.2% | ||
| Q3 25 | — | 12.0% | ||
| Q2 25 | — | 9.3% | ||
| Q1 25 | — | 10.4% | ||
| Q4 24 | — | 16.7% | ||
| Q3 24 | — | 5.0% | ||
| Q2 24 | — | 13.8% | ||
| Q1 24 | -354327.8% | 8.7% |
净利率BBLGCDRE
| Q4 25 | — | 7.0% | ||
| Q3 25 | — | 7.0% | ||
| Q2 25 | — | 7.8% | ||
| Q1 25 | — | 7.1% | ||
| Q4 24 | — | 7.4% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | 8.7% | ||
| Q1 24 | -339596.1% | 5.0% |
每股收益（稀释后）BBLGCDRE
| Q4 25 | — | $0.22 | ||
| Q3 25 | — | $0.27 | ||
| Q2 25 | — | $0.30 | ||
| Q1 25 | — | $0.23 | ||
| Q4 24 | — | $0.32 | ||
| Q3 24 | — | $0.09 | ||
| Q2 24 | — | $0.31 | ||
| Q1 24 | $-1.31 | $0.18 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $122.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $3.7M | $317.8M |
| 总资产 | $3.8M | $770.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BBLGCDRE
| Q4 25 | — | $122.9M | ||
| Q3 25 | — | $150.9M | ||
| Q2 25 | — | $137.5M | ||
| Q1 25 | — | $133.4M | ||
| Q4 24 | — | $124.9M | ||
| Q3 24 | — | $93.0M | ||
| Q2 24 | — | $105.9M | ||
| Q1 24 | — | $87.1M |
股东权益BBLGCDRE
| Q4 25 | — | $317.8M | ||
| Q3 25 | — | $340.4M | ||
| Q2 25 | — | $332.5M | ||
| Q1 25 | — | $317.6M | ||
| Q4 24 | — | $311.5M | ||
| Q3 24 | — | $300.3M | ||
| Q2 24 | — | $299.4M | ||
| Q1 24 | $3.7M | $270.7M |
总资产BBLGCDRE
| Q4 25 | — | $770.0M | ||
| Q3 25 | — | $792.1M | ||
| Q2 25 | — | $794.4M | ||
| Q1 25 | — | $656.3M | ||
| Q4 24 | — | $652.7M | ||
| Q3 24 | — | $616.6M | ||
| Q2 24 | — | $620.6M | ||
| Q1 24 | $3.8M | $599.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.3M | $21.3M |
| 自由现金流经营现金流 - 资本支出 | — | $18.0M |
| 自由现金流率自由现金流/营收 | — | 10.7% |
| 资本支出强度资本支出/营收 | — | 2.0% |
| 现金转化率经营现金流/净利润 | — | 1.81× |
| 过去12个月自由现金流最近4个季度 | — | $56.8M |
8季度趋势，按日历期对齐
经营现金流BBLGCDRE
| Q4 25 | — | $21.3M | ||
| Q3 25 | — | $22.5M | ||
| Q2 25 | — | $2.6M | ||
| Q1 25 | — | $17.4M | ||
| Q4 24 | — | $23.7M | ||
| Q3 24 | — | $-5.2M | ||
| Q2 24 | — | $11.1M | ||
| Q1 24 | $-1.3M | $2.1M |
自由现金流BBLGCDRE
| Q4 25 | — | $18.0M | ||
| Q3 25 | — | $21.6M | ||
| Q2 25 | — | $1.2M | ||
| Q1 25 | — | $16.1M | ||
| Q4 24 | — | $22.4M | ||
| Q3 24 | — | $-6.2M | ||
| Q2 24 | — | $9.1M | ||
| Q1 24 | — | $794.0K |
自由现金流率BBLGCDRE
| Q4 25 | — | 10.7% | ||
| Q3 25 | — | 13.9% | ||
| Q2 25 | — | 0.7% | ||
| Q1 25 | — | 12.4% | ||
| Q4 24 | — | 12.7% | ||
| Q3 24 | — | -5.7% | ||
| Q2 24 | — | 6.3% | ||
| Q1 24 | — | 0.6% |
资本支出强度BBLGCDRE
| Q4 25 | — | 2.0% | ||
| Q3 25 | — | 0.5% | ||
| Q2 25 | — | 0.9% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | 0.7% | ||
| Q3 24 | — | 0.9% | ||
| Q2 24 | — | 1.4% | ||
| Q1 24 | — | 1.0% |
现金转化率BBLGCDRE
| Q4 25 | — | 1.81× | ||
| Q3 25 | — | 2.05× | ||
| Q2 25 | — | 0.21× | ||
| Q1 25 | — | 1.88× | ||
| Q4 24 | — | 1.83× | ||
| Q3 24 | — | -1.43× | ||
| Q2 24 | — | 0.89× | ||
| Q1 24 | — | 0.31× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BBLG
暂无分部数据
CDRE
| U.s.state And Local Agencies | $72.7M | 43% |
| Other | $48.6M | 29% |
| U.s.Federal Agencies | $31.6M | 19% |
| Commercial | $12.0M | 7% |
